OKYO to Participate at Biotech Showcase
21 déc. 2022 02h00 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, Dec. 21, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye...
OKYO Pharma Limited ("OKYO" or the "Company") - OKYO publicly files a registration statement with the SEC
06 déc. 2022 02h00 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye...
OKYO Pharma Limited - Change of Auditor
01 déc. 2022 02h00 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye...
OKYO Pharma Limited – PDMR dealing
24 nov. 2022 02h00 HE
|
OKYO Pharma LTD
LONDON and BOSTON, Nov. 24, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye...
OKYO Pharma Announces U.S. IND Filing on OK-101 for the Treatment of Dry Eye Disease
21 nov. 2022 02h00 HE
|
OKYO Pharma LTD
-OK-101 first-in-human Phase 2 trial will incorporate primary and secondary efficacy endpoints characterizing signs and symptoms of Dry Eye Disease- LONDON and BOSTON, Nov. 21, 2022 (GLOBE...
OKYO Pharma Hosting Key Opinion Leader Event Introducing OK-101 as a Potential Treatment for Dry Eye Disease
10 nov. 2022 06h00 HE
|
OKYO Pharma LTD
Monday, November 14th @ 8 am ET, registration details below NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Ltd (Nasdaq: OKYO; LSE: OKYO) (“OKYO” or the “Company”), an ophthalmology...
OKYO Pharma Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report®
08 sept. 2022 09h25 HE
|
OKYO Pharma LTD
NEW YORK and LONDON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO; LSE: OKYO;), a biotechnology company focused on the discovery and development of novel molecules to treat...
OKYO Pharma Limited: Result of Annual General Meeting
07 sept. 2022 09h00 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- The board of directors of OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a bio-pharmaceutical company focused on developing an innovative...
OKYO Pharma Plans Q4 2022 IND Filing of OK-101 to treat Dry Eye Disease with Subsequent Phase 2 Initiation Alongside Peptide Manufacturing Partner, AmbioPharm
30 août 2022 02h00 HE
|
OKYO Pharma LTD
OK-101 to treat ocular diseases, including Dry Eye Disease (DED), uveitis, allergic conjunctivitis, and ocular pain.Successful pre-IND meeting with FDA in Q1 2022 and novel speed to market...
OKYO Pharma Limited - Final audited results for the year ended 31 March 2022
16 août 2022 02h00 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO; LSE: OKYO) (the “Company”) is pleased to announce its final audited results for the year ended 31 March...